AlphaVax has landed its third major contract over the past 18 months for vaccine development, the latest one worth $3.3 million to develop a smallpox vaccine.

AlphaVax received the grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, earlier this week.

The award follows a $5 million-plus contract for flu vaccine awarded earlier this year and a $4.8 million grant for SARS research in April of last year.